Social Media Ideas for Azurity Pharmaceuticals

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Zanvastro]]>

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

AbbVie Seeks Block On Alkem Generic Constipation Drug

AbbVie Inc. and collaborator Ironwood Pharmaceuticals urged a New Jersey federal court to bar India-based generic drugmaker Alkem Laboratories from selling generic versions of thei...

<![CDATA[Pharmaceutical Executive Daily: Jazz Acquires Actio Bioscience]]>

Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug

Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca...

<![CDATA[Aptar and Aceso Therapeutics Enter Collaboration for Cystic Fibrosis Therapy ]]>

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

<![CDATA[Pharmaceutical Executive Daily: AstraZeneca and Bristol Myers Squibb Held Merger Talks]]>

Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets

Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZeneca’s Lynparza. The dr...

Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug

Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecul...

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Orezeyful]]>

Nationwide Recall Issued for Cetirizine (Zyrtec Generic)

Four lots of generic cetirizine were recalled nationwide after possible ranitidine contamination, posing a serious allergy risk to susceptible consumers. The post Nationwide Recall...

Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug

Sentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.

<![CDATA[FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults ]]>

AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD

With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it b...

<![CDATA[AstraZeneca and Bristol Myers Squibb Held Merger Talks: Report]]>

Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial

Atea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment...

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

Crystalys mines $130M series B to push gout drug through phase 3

Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a note...

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)